Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management

Journal of Neuroimmunology

Volumn 239, Issue 1-2, 2011, Pages 1-12

  Gambuzza, M ^a   Licata, N ^b   Palella, E ^b   Celi, D ^b   Foti Cuzzola, V ^b   Italiano, D ^b   Marino, S ^b   Bramanti, P ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Innovative therapeutics; Multiple sclerosis; Receptor targeting; Toll like receptors

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; CHAPERONIN; CPG OLIGODEOXYNUCLEOTIDE; E 5531; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOMODULATING AGENT; IMO 3100; ISIS 337846; MCT 465; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; OPN 305; PLACEBO; POLYINOSINIC POLYCYTIDYLIC ACID; RABEXIMOD; RECOMBINANT CHAPERONIN 10; RESATORVID; RINTATOLIMOD; ST 2825; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BRAIN CANCER; CHRONIC FATIGUE SYNDROME; CPG ISLAND; DENDRITIC CELL; DIMERIZATION; DRUG DOSE ESCALATION; DRUG INDICATION; ENDOTOXEMIA; HEPATITIS; HOMODIMERIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INFLAMMATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NEUROINFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CARCINOMA IN SITU;

ANIMALS; COMPLEMENTARY THERAPIES; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 80054934482     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.08.010     Document Type: Review

References (113)

1. Akira S. Innate immunity to pathogens: diversity in receptors for microbial recognition. Immunol. Rev. 2009, 227:5-8.
2. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
3. Andersson A., Covacu R., Sunnemark D., Danilov A.I., Dal Bianco A., Khademi M., Wallström E., Lobel A., Brundin L., Lassmann H., Harris R.A. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J. Leukoc. Biol. 2008, 84:1248-1255.
4. Andreakos E., Foxwell B., Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunol. Rev. 2004, 202:250-265.
5. Arslan F., de Kielijn D.P., Timmers L., Doevendands P.A., Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion in injury: the search for therapeutic targets. Curr. Pharm. Des. 2008, 14:1205-1216.
6. Barrat F.J., Coffman R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 2008, 223:271-283.
7. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., Chang B., Duramad O., Coffman R.L. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 2005, 202:1131-1139.
8. Barrat F.J., Meeker T., Chan J.H., Guiducci C., Coffman R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007, 37:3582-3586.
9. Bartfai T., Behrens S., Gaidarova S., Pemberton J., Shivanyuk A., Rebek J. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7971-7976.
10. Barton G.M., Kagan J.C., Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 2006, 7:49-56.
11. Bayas A., Stasiolek M., Kruse N., Toyka K.V., Selmaj K., Gold R. Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis. Clin. Exp. Immunol. 2009, 157:332-342.
12. Bennett-Guerrero E., Grocott H.P., Levy J.H., Stierer K.A., Hogue C.W., Cheung A.T., Newman M.F., Carter A.A., Rossignol D.P., Collard C.D. A Phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (EE5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth. Analg. 2007, 104:378-383.
13. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
14. Broadley S.A., Vanags D., Williams B., Johnson B., Feeney D., Griffiths L., Shakib S., Brown G., Coulthard A., Mullins P., Kneebone C. Results of a Phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult. Scler. 2009, 15:329-336.
15. Bsibsi M., Bajramovic J.J., Vogt M.H., van Duijvenvoorden E., Baghat A., Persoon-Deen C., Tielen F., Verbeek R., Huitinga I., Ryffel B., Kros A., Gerritsen W.H., Amor S., van Noort J.M. The microtubule regulator stathmin is an endogenous protein agonist for TLR3. J. Immunol. 2010, 184:6929-6937.
16. Carpenter S., O'Neill L.A. Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem. J. 2009, 422:1-10. (Review).
17. Caso J.R., Pradillo J.M., Hurtado O., Lorenzo P., Moro M.A., Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115:1599-1608.
18. Chang Y.C., Kao W.C., Wang W.Y., Yang R.B., Peck K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB 2009, 23:3078-3088.
19. Chearwae W., Bright J.J. 15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of Toll-like receptors 4 and 9 in autoimmune T lymphocyte. J. Clin. Immunol. 2008, 28:558-570.
20. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., Wang J.M. Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 2007, 7:1271-1285.
21. Chi H., Flavell R.A. Innate recognition of non-self nucleic acids. Genome Biol. 2008, 9:211.1-211.6.
22. Christ W.J., Asano O., Robidoux A.L., Perez M., Wang Y., Dubuc G.R., Gavin W.E., Hawkins L.D., McGuinness P.D., Mullarkey M.A., Lewis M.D., Kishi Y., Kawata T., Bristol J.R., Rose J.R., Rossignol D.P., Kobayashi S., Hishinuma L., Kimura A., Asakawa N., Katayama K., Yamatsu I. E5531, a pure endotoxin antagonist of high potency. Science 1995, 268:80-83.
23. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
24. Correale G., Farez M. Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms. J. Immunol. 2009, 183:5999-6012.
25. Dillon S., Agrawal S., Banerjee K., Letterio J., Denning T.L., Oswald-Richter K., Kasprowicz D.J., Kellar K., Pare J., van Dyke T., Ziegler S., Unutmaz D., Pulendram B. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 2006, 116:916-928.
26. Dorner M., Brandt S., Tinguely M., Zucol F., Bourquin J.P., Zauner L., Berger C., Bernasconi M., Speck R.F., Nadal D. Plasma cell Toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009, 128:573-579.
27. Downer E.J., Clifford E., Gran B., Nel H.J., Fallon P.G., Moynagh P.N. Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J. Biol. Chem. 2011, 286:10316-10328.
28. Drexler S.K., Foxwell B.M. The role of Toll-like receptors in chronic inflammation. Int. J. Biochem. Cell Biol. 2010, 42:506-518.
29. Dunn-Siegrist I., Leger O., Daubeuf B., Poitevin Y., Dépis F., Herren S., Kosco-Vilbois M., Dean Y., Pugin J., Elson G. Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J. Biol. Chem. 2007, 282:34817-34827.
30. Duramad O., Fearon K.L., Chang B., Chang J.H., Gregorio J., Coffman R.J., Barrat F.J. Inhibitors of TLR9 act on multiple cell subsets in mouse and man "in vitro" and prevent death "in vivo" from systemic inflammation. J. Immunol. 2005, 174:5193-5200.
31. Eitan O., Kathleen J.G., Justin D.L., Sung-Chun T., Thiruma V.A. Toll-like receptors in neurodegeneration. Brain Res. Rev. 2009, 59:278-292.
32. Fort M.M., Mozaffarian A., Stoäver A.G., Correia Jda S., Johnson D.A., Crane R.T., Ulevitch R.J., Persing D.H., Bielefeldt-Ohmann H., Probst P., Jeffery E., Fling S.P., Hershberg R.M. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J. Immunol. 2005, 174:6416-6423.
33. Galdiero M., Galdiero M., Finamore E., Rossano F., Gambuzza M., Catania M.R., Teti G., Midiri A., Mancuso G. Haemophilus influenzae porin induces Toll-like receptor 2-mediated cytokine production in human monocytes and mouse macrophages. Infect. Immun. 2004, 72:1204-1209.
34. Gandhi R., Laroni A., Weiner H.L. Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2010, 221:7-14.
35. Gay N.J., Keith F.J. Drosophila Toll and IL-1 receptor. Nature 1991, 351:355-356.
36. Glezer I., Chernomoretz A., David S., Plante M.M., Rivest S. Genes involved in the balance between neuronal survival and death during inflammation. PloS One 2007, 21:2-e310.
37. Hennessy E.J., Parker A.E., O'Neill L.A. Targeting Toll-like receptors: emerging therapeutics?. Nat. Rev. Drug. Discov. 2010, 9:293-307.
38. Hodgkinson L. Digestive Disease Week 2010. Turning science into medicine-part 2. IDrugs 2010, 13:424-426.
39. Hua F., Ma J., Ha T., Xia Y., Kelley J., Williams D.L., Kao R.L., Browder I.W., Schweitzer J.B., Kalbfleisch J.H. Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. J Neuroimmunol 2007, 190:101-111.
40. Hultqvist M., Nandakumar K.S., Björklund U., Holmdah R. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse model of autoimmune disorders. Ann. Rheum. Dis. 2009, 68:130-135.
41. Hultqvist M., Nandakumar K.S., Bjorklund U., Holmdahl R. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann. Rheum. Dis. 2010, 69:1527-1532.
42. Ishii K.J., Takeshita F., Gursel I., Gursel M., Conover J., Nussenzweig A., Klinman D.M. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med. 2002, 196:269-274.
43. Iwami K., Matsuguchi T., Masuda A., Kikuchi T., Musikacharoen T., Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J. Immunol. 2000, 165:662-668.
44. Iyer S., Kontoyiannis D., Chevrier D., Woo J., Mori N., Cornejo M., Kollias G., Buelow R. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J. Biol. Chem. 2000, 275:17051-17057.
45. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31:3388-3393.
46. Jasani B., Navabi H., Adams M. Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009, 27:3401-3404.
47. Johnson B.J., Le T.T., Dobbin C.A., Banovic T., Howard C.B., Flores Fde M., Vanags D., Naylor D.J., Hill G.R., Suhrbier A. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J. Biol. Chem. 2005, 280:4037-4047.
48. Kagan J.C., Su T., Horng T., Chow A., Akira S., Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 2008, 9:361-368.
49. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13:552-559.
50. Kawai T., Akira S. Signaling to NF-kappa B by Toll-like receptors. Trends Mol. Med. 2007, 13:460-469.
51. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
52. Keller J.N., Hanni K.B., Gabbita S.P., Friebe V., Mattson M.P., Kindy M.S. Oxidized lipoproteins increase reactive oxygen species formation in microglia and astrocyte cell lines. Brain Res. 1999, 830:10-15.
53. Kenny E.F., O'Neill L.A. Signaling adaptors used by Toll-like receptors: an update. Cytokine 2008, 43:342-349.
54. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J.C., Yamasaki S., Itaya M., Pan Y., Appukuttan B., Gibbs D., Yang Z., Karikò K., Ambati B.K., Wilgus T.A., Di Pietro L.A., Sakurai E., Zhang K., Smith J.R., Taylor E.W., Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:543-545.
55. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J. Neurol. Sci. 2008, 274:45-47. Review.
56. Ledeboer A., Hutchinson M.R., Watkins L.R., Johnson K.W. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert. Opin. Investig. Drugs 2007, 16:935-950.
57. Lee J.S., Lee J.Y., Lee M.Y., Hwang D.H., Youn H.S. Acrolein with an alpha, beta-unsaturated carbonyl group inhibits LPS-induced homodimerization of Toll-like receptor 4. Mol. Cells 2008, 25:253-257.
58. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58:253-263.
59. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., Volpe J.J., Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8514-8519.
60. Li Y., Chu N., Hu A., Gran B., Rostami A., Zhang G.X. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007, 130:490-501.
61. Loiarro M., Capolunghi F., Fantò N., Gallo G., Campo S., Arseni B., Carsetti R., Carminati P., De Santis R., Ruggiero V., Sette C. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J. Leuk. Biol. 2007, 82:801-810.
62. Mancuso G., Midiri A., Biondo C., Beninati C., Gambuzza M., Macrì D., Bellantoni A., Weintraub A., Espevik T., Teti G. Bacteroides fragilis-derived lipopolysaccharide produces cell activation and lethal toxicity via Toll-like receptor 4. Infect. Immun. 2005, 73:5620-5627.
63. Mancuso G., Gambuzza M., Midiri A., Biondo C., Papasergi S., Akira S., Teti G., Beninati C. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat. Immunol. 2009, 10:587-594.
64. Marsh B.J., Stenzel-Poore M.P. Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr. Opin. Pharmacol. 2008, 8:8-13.
65. Marta M. Toll-like receptors in multiple sclerosis mouse experimental models. Ann. N.Y. Acad. Sci. 2009, 1173:458-462.
66. Marta M., Andersson A., Isaksson M., Kämpe O., Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2008, 38:565-575.
67. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8:913-919.
68. Meng G., Rutz M., Schiemann M., Metzger J., Grabiec A., Schwandner R., Luppa P.B., Ebel F., Busch D.H., Bauer S., Wagner H., Kirschning C.J. Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invests 2004, 113:1473-1481.
69. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., Manning S., Greenfield E.A., Coyle A.J., Sobel R.A., Freeman G.J., Kuchroo V.K. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
70. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., Chow J.C., Strauss J.F. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 2001, 276:10229-10233.
71. Okun E., Griffioen K.J., Lathia J.D., Tang S.C., Mattson M.P., Arumugam T.V. Toll-like receptors in neurodegeneration. Brain Res. Rev. 2008, 59:278-292.
72. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004, 173:3916-3924.
73. O'Neill L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 2006, 5:549-563.
74. O'Neill L.A., Bryant C.E., Doyle S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 2009, 61:177-197.
75. Pawar R.D., Ramanjaneyulu A., Kulkarni O.P., Lech M., Segerer S., Anders H.J. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 2007, 18:1721-1726.
76. Pedras-Vasconcelos J., Puig M., Verthelyi D. TLRs as therapeutic targets in CNS inflammation and infection. Front. Biosci. 2009, 1:476-487.
77. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010, 2010, 672395.
78. Prinz M., Garbe F., Schmidt H., Mildner A., Gutcher I., Wolter K., Piesche M., Schroers R., Weiss E., Kirschning C.J., Rochford C.D., Bruck W., Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006, 116:456-464.
79. Pulendran B., Tang H., Manicassamy S. Programming dendritic cells to induce TH2 and tolerogenic responses. Nat. Immunol. 2010, 11:647-655.
80. Racke M.K., Drew P.D. Toll-like receptors in multiple sclerosis. Curr. Top. Microbiol. Immunol. 2009, 336:155-168.
81. Robinson R.A., De Vita V.T., Levy H.B., Baron S., Hubbard S.P., Levine A.S. A Phase I-II trial of multiple-dose polyriboinosinic-polyribocytidylic acid in patients with leukemia or solid tumors. J. Natl. Cancer Inst. 1976, 57:599-602.
82. Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:588-593.
83. Sarnico I., Lanzillotta A., Benarese M., Alghisi M., Baiguera C., Battistin L., Spano P., Pizzi M. NF-kappaB dimers in the regulation of neuronal survival. Int. Rev. Neurobiol. 2009, 85:351-362.
84. Schmidt C. Immune system's Toll-like receptors have good opportunity for cancer treatment. J. Natl. Cancer Inst. 2006, 98:574-575.
85. Simon B.R., Line S.R., Paludan S.R. Innate recognition of intracellular pathogens: detection and activation of the first line of defense. APMIS 2009, 117:323-327.
86. Slack E.C., Robinson M.J., Hernanz-Falcon P., Brown G.D., Williams D.L., Schweighoffer E., Tybulewicz V.L., Reis e Sousa C. Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Eur. J. Immunol. 2007, 37:1600-1612.
87. Sloane J.A., Blitz D., Margolin Z., Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromolecular Med. 2010, 12:149-163. Review.
88. Sloane J.A., Batt C., Ma Y., Harris Z.M., Trapp B., Vartarian T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc. Natl. Acad. Sci. 2010, 25:11555-11560.
89. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
90. Stein R.C., Waterfield M.D. PI3-kinase inhibition; a target for drug development?. Mol. Med. Today 2000, 6:347-357.
91. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2009, 11:155-161.
92. Strayer D.R., Carter W.A., Brodsky I., Cheney P., Peterson D., Salvato P., Thompson C., Loveless M., Shapiro D.E., Elsasser W. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin. Infect. Dis. 1994, 18:S88-S95.
93. Sullivan T., Atiee G., Bhagat L., Jiang W., Kandimalla E., Murphy J., Precopio M., Putta M., Arbei R. Safety and pharmacodynamics of IMO-3100, a novel Toll-like receptor antagonist for autoimmune and inflammatory diseases, in a rising single-dose phase I clinical trial. 6th Annual Meeting of the Oligonucleotide Therapeutic Society being Held in Dana Point, California, Oct 20-23 2010.
94. Sun S., Rao N.L., Venable J., Thurmond R., Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets 2007, 6:223-235.
95. Takashima K., Matsunaga N., Yoshimatsu M., Hazeki K., Kaisho T., Uekata M., Hazeki O., Akira S., Iizawa Y., Ii M. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br. J. Pharmacol. 2009, 157:1250-1252.
96. Touil T., Fitzgerald D., Zhang G.X., Rostami A., Gran B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-β. J. Immunol. 2006, 177:7505-7509.
97. Trieu A., Roberts T.L., Dunn J.A., Sweet M.J., Stacey K.J. DNA motifs suppressing TLR9 responses. Clin. Rev. Immunol. 2006, 26:527-544.
98. Tseng P.H., Matsuzawa A., Zhang W., Mino T., Vignali D.A.A., Karin M. Different modes of ubiquination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat. Immunol. 2010, 11:70-75.
99. Ungaro R., Fukata M., Hsu D., Hernandez Y., Breglio K., Chen A., Xu R., Sotolongo J., Espana C., Zaias J., Elson G., Mayer L., Kosco-Vilbois M., Abreu M.T. A novel Toll-like receptor 4 (TLR4) antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G1167-G1179.
100. Urbonaviciute V., Fürnrohr B.G., Meister S., Munoz L., Heyder P., De Marchis F., Bianchi M.E., Kirschning C., Wagner H., Manfredi, Kalden J.R., Schett G., Rovere-Querini P., Herrmann M., Voll R.E. Induction of inflammatory and immune responses by HMGB 1-nucleosome complexes implications for the pathogenesis of SLE. J. Exp. Med. 2008, 205:3007-3018.
101. Vaishnaw A.K., Gollob J., Gamba-Vitalo C., Hutabarat R., Sah D., Meyers R., de Fougerolles T., Maraganore J. A status report on RNAi therapeutics. Silence 2010, 8:1-14.
102. van Eden W. XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. Curr. Opin. Investig. Drugs 2008, 9:523-533. (Review).
103. Veldhoen W., Hocking R.J., Flavell R.A., Stockinger B. 2006. Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat. Immunol. 7, 1151-1156.
104. Von Bernuth H., Picard C., Jin Z., Pankla R., Xiao H., Ku C.L., Chrabieh M., Mustapha I.B., Ghandil P., Camcioglu Y., Vasconcelos J., Sirvent N., Guedes M., Vitor A.B., Herrero-Mata M.J., Aróstegui J.I., Rodrigo C., Alsina L., Ruiz-Ortiz E., Juan M., Fortuny C., Yagüe J., Antón J., Pascal M., Chang H.H., Janniere L., Rose Y., Garty B.Z., Chapel H., Issekutz A., Maródi L., Rodriguez-Gallego C., Banchereau J., Abel L., Li X., Chaussabel D., Puel A., Casanova J.L. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008, 321:691-696.
105. Waldner H., Collins M., Kuchroo V.K. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 2004, 113:990-997.
106. Wang D., Bhagat L., Yu D., Zhu F.G., Tang J.X., Kandimalla E.R., Agrawal S. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J. Med. Chem. 2009, 52:551-558.
107. Watters T.M., Kenny E.F., O'Neil lL.A. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol. Cell Biol. 2007, 85:411-419.
108. Weiner H.L. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch. Neurol. 2004, 61:1613-1615.
109. Weiner H.L. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 2008, 255:3-11.
110. Wittebole X., Castanares-Zapatero D., Laterre P.F. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm. 2010, 568396. Review.
111. Yong V.W., Marks S. The interplay between the immune and central nervous systems in neuronal injury. Neurology 2010, 74:S9-S16.
112. Yu L., Wang L., Chen S. Endogenous Toll-like receptor ligands and their biological significance. J. Cell Mol. Med. 2010, 14:2592-2603.
113. Zhang X., Jin J., Tang Y., Speer D., Sujkowska D., Markovic-Plese S. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J. Immunol. 2009, 182:3928-3936.